HIV vaccine - Profectus Biosciences

Drug Profile

HIV vaccine - Profectus Biosciences

Alternative Names: HIV-1 vaccine - Profectus Biosciences; HIV-1-gag-vaccine; Recombinant vesicular stomatitis virus HIV-1 gag vaccine; rVSV HIV vaccine - Profectus Biosciences; rVSV HIV-1 gag vaccine; rVSVIN HIV-1 gag vaccine; rVSVN4CT1 HIV

Latest Information Update: 04 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Profectus Biosciences
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 31 Oct 2014 Profectus in-licenses vaccine delivery technology from Yale University prior to October 2014
  • 17 Sep 2013 Phase-I clinical trials in HIV infections in USA (IM)
  • 04 Dec 2012 Final adverse events and immunogenicity data from a phase I trial in HIV infection (prevention) released by Profectus Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top